Navigation Links
Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
Date:7/21/2008

Anadis Ltd (ASX:ANX; OTC:ANDIY), a biopharmaceutical company focused on research, development and production of immune milk (colostrum)-derived polyclonal antibodies and other proteins to address major diseases, today announces the initiation of a clinical trial with top clinical scientists at Tel Aviv Sourasky Medical Center in Israel. The clinical trial will explore the efficacy of a formulation developed by Anadis to address the symptoms of Inflammatory Bowel Disease (IBD), a serious chronic condition effecting millions of persons annually.

MELBOURNE, Australia (Business Wire EON) July 21, 2008 -- About 4 million people worldwide suffer from Inflammatory Bowel Disease, split roughly evenly between the two manifestations of the disease: Crohn's disease (CD) and ulcerative colitis (UC). IBD is a relapsing / remitting chronic disease with gastrointestinal symptoms such as diarrhoea, rectal bleeding and abdominal pain.

The study is led by a leading Israeli Gastroenterologist, Professor Zamir Halpern, Deputy Director of Tel Aviv Sourasky Medical Center and Chief of the Center's Gastroenterology Institute, and by Professor Nachum Vaisman, Head of the Unit of Clinical Nutrition.

The first patients have already been recruited and have entered the trial which is expected be completed during 2009. The trial is designed as an open study being run to confirm and expand upon human clinical data obtained from a pilot study at St Vincent's Hospital in Melbourne, which ended recently. Anadis intends to launch its colostrum-derived product as a medical food or nutritional immediately following the Tel Aviv trial. Anadis will meet all regulatory requirements during the conduct of the trial itself.

In addition to the initiation of this IBD study, Anadis recently announced being awarded a VISTECH grant for another study, also to be conducted at Tel Aviv Souraski Medical Center, towards the development and commercialization of a product to address cancer-related mucositis. See "Anadis Awarded VISTECH grant for Clinical Trial of Polyclonal Antibodies for the Treatment of Cancer Related Mucositis" - Tuesday 1 July 2008."

Tel Aviv Sourasky Medical Center (TASMC) is one of the largest hospitals in Israel with 1100 beds and is responsible for providing specialty care to the Tel Aviv metropolitan area. It is a teaching and research center affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dr Oren Fuerst, VP Business development of Anadis stated, "This is another illustration of the successful collaboration between Anadis and the researchers at TASMC. The leveraging of Australian manufacturing and core research, with research and clinical studies in Israel will allow us to bring products to market faster and at lower costs than otherwise. Our current plans calls for commercialization of both the IBD and the mucositis products within less than 2 years, addressing two major gastrointestinal diseases using our core platform."

Read the full story at http://www.prweb.com/releases/tel_aviv/anadis/prweb1132164.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
2. North Carolinas Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center
3. Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes
4. Northwestern Memorial Among Americas Best Hospitals in 10 Clinical Specialties According to U.S. News 2008 Rankings
5. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
6. Termination of IS Clinical From Distributing PhytoCeuticals Formulas
7. Dr. Howard Epstein Joins Blue Cross as Medical Director for Commercial Operations and Clinical Design
8. Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition
9. Clinical Launch of Innovative Cloth Sleep Apnea Mask Creates Buzz at Sleep Conference
10. New clinical trial for patients with asbestos-associated lung cancer
11. Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... an unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated ... a patient has signs and symptoms consistent with Zikas and a travel history ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... for nominations seeking candidates for the Board of Commissioners. Individuals interested in volunteer ... and experience with diversity of clinical practice settings and across allied health to ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... trainer and author Ray Clarke poses a question as a challenge for his ... his book, "Being in the Being" (published by Partridge Singapore), Clarke explores the ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, ... and audits, privacy and security law, and best practices in data breaches for ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Life is ... group of men, 60 and older, who gather once a year to play softball ... a love for the game, the more than 50 players who competed in this ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... MEMPHIS, Tenn. , Feb. 11, 2016 ... a promising new treatment method at West Cancer ... low intensity electric fields to inhibit cancer cell replication ... therapy in more than a decade to show a ... adult Glioblastoma Multiforme (GBM) patients. Currently, West Cancer Center ...
(Date:2/11/2016)... 11, 2016 --> ... new research report, titled "Sports Medicine Devices Market - Global ... 2019". According to the report, the global sports medicine devices ... 2013 to 2019, growing from a value of US$6.1 bn ... --> --> The global sports medicine devices ...
(Date:2/11/2016)... NORTH CHICAGO, Ill. , Feb. 11, 2016 ... launch of the AbbVie Rheumatology Scholarship, designed to ... a rheumatologic disease as they pursue higher education ... $15,000 each for the 2016-2017 school year. The ... Tracie Haas , vice president, corporate ...
Breaking Medicine Technology: